NT5C1B and Sepsis: This international, multicenter, retrospective, nonrandomized, controlled, outcome-blinded, genotype-blinded, and matched-patients study found that neither IRP A nor IRP B predicted differential DrotAA treatment effects on in-hospital mortality through Day 28 in patients with severe sepsis.